TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26343814

Group type: COMPARATOR
Intervention: Empagliflozin (12 weeks, cohort 1)
Number of subjects: 3300

Group type: COMPARATOR
Intervention: Empagliflozin (24 weeks, cohort 2)
Number of subjects: 3300

Group type: COMPARATOR
Intervention: Empagliflozin (cohort 1)
Number of subjects: 3300

Group type: COMPARATOR
Intervention: Empagliflozin (cohort 2)
Number of subjects: 3300
Study: 23621201

Group type: EXPERIMENTAL
Intervention: Individual Counseling Group (ICG)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Group Counseling Group (GCG)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control Counseling Group (CCG)
Number of subjects: 150
Study: 21933348

Group type: EXPERIMENTAL
Intervention: Flibanserin (50 mg or 100 mg/day)
Number of subjects: 738

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 738
Study: 19255824

Group type: EXPERIMENTAL
Intervention: Combination therapy with 50 mg of losartan plus 12.5 mg of hydrochlorothiazide
Number of subjects: 32

Group type: COMPARATOR
Intervention: Monotherapy with 160 mg of valsartan
Number of subjects: 32
Study: 16421661

Group type: EXPERIMENTAL
Intervention: Preoperative oral intake supplementation with a formula enriched with arginine, omega-3 fatty acids and ribonucleic acid for five days (supplemented group; n = 19)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (n = 17)
Number of subjects: 36
Study: 15614033

Group type: EXPERIMENTAL
Intervention: Low-dose combination of perindopril (2 mg) and indapamide (0.625 mg)
Number of subjects: 533

Group type: COMPARATOR
Intervention: Sequential monotherapy (atenolol 50 mg, losartan 50 mg, amlodipine 5 mg)
Number of subjects: 533

Group type: COMPARATOR
Intervention: Stepped-care (valsartan 40 mg, valsartan 80 mg, hydrochlorothiazide 12.5 mg)
Number of subjects: 533
Study: 11159107

Group type: EXPERIMENTAL
Intervention: Sulcal hyperintensity on FLAIR images
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Dirty CSF sign
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Abnormal contrast enhancement
Number of subjects: 291
Study: 9404442

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement therapy (0.125 iu/kg/week for the first month and 0.25 iu/kg/week for the following 5 months)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 8115311

Group type: EXPERIMENTAL
Intervention: Isradipine plain formulation (2.5 mg twice daily)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Isradipine slow release formulation (5.0 mg once daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Both formulations
Number of subjects: 30
Study: 3303424

Group type: EXPERIMENTAL
Intervention: Ketoconazole (400 mg daily)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ketoconazole (in asthmatic patients)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (in asthmatic patients)
Number of subjects: 10
Study: 30874799

Group type: EXPERIMENTAL
Intervention: Treadmill training with non-immersive virtual reality intervention
Number of subjects: 39

Group type: COMPARATOR
Intervention: Treadmill training
Number of subjects: 39
Study: 29676870

Group type: EXPERIMENTAL
Intervention: Thiazide-like diuretics (e.g., chlorthalidone, indapamide)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low dose thiazide-like diuretics
Number of subjects: 0
Study: 29037203

Group type: EXPERIMENTAL
Intervention: Team Nutriathlon (web-based nutrition intervention)
Number of subjects: 282

Group type: COMPARATOR
Intervention: Control group (regular school curriculum)
Number of subjects: 282
Study: 26530748

Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy (EBRT)
Number of subjects: 427

Group type: COMPARATOR
Intervention: Vaginal Brachytherapy (VBT)
Number of subjects: 427
Study: 23132892

Group type: EXPERIMENTAL
Intervention: Web/Mail
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mail Only
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SE-IVR/Phone
Number of subjects: 0
Study: 21813076

Group type: EXPERIMENTAL
Intervention: Aripiprazole (2-15 mg/d)
Number of subjects: 330
Study: 17665078

Group type: EXPERIMENTAL
Intervention: 1% propofol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1% propofol + 0.5 mg.ml‐1 ephedrine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1% propofol + 1.0 mg.ml‐1 ephedrine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (1% propofol without ephedrine)
Number of subjects: 60
Study: 15343012

Group type: EXPERIMENTAL
Intervention: Antithrombin supplementation (n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional intensive care treatment (n = 20, controls)
Number of subjects: 40
Study: 11166779

Group type: EXPERIMENTAL
Intervention: Etofibrate (1 g per day for 1 month)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9699104

Group type: EXPERIMENTAL
Intervention: Unilateral intercostal nerve block with 0.5% bupivacaine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 50
Study: 8148216

Group type: EXPERIMENTAL
Intervention: Acoustic rhinometry
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Active posterior rhinomanometry
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cetirizine, 10 mg orally, 3 h before repeat nasal challenge with histamine
Number of subjects: 40
Study: 2500006

Group type: EXPERIMENTAL
Intervention: Lithium carbonate added to carbamazepine
Number of subjects: 7

Group type: COMPARATOR
Intervention: Carbamazepine alone
Number of subjects: 7
Study: 31126103

Group type: EXPERIMENTAL
Intervention: Collagen peptides (COL, 15 g/day)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Collagen peptides (COL) and Placebo (PLA)
Number of subjects: 57
Study: 29058153

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (no GH treatment)
Number of subjects: 11
Study: 27394932

Group type: EXPERIMENTAL
Intervention: TV-1380 (150mg)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: TV-1380 (300mg)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 24666826

Group type: EXPERIMENTAL
Intervention: Half-molar sodium lactate infusion (3 ml/kg bolus over 15 minutes followed by 1 ml/kg/h continuous infusion for 24 hours)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Hartmann's solution (3 ml/kg bolus without continuous infusion)
Number of subjects: 40
Study: 22201291

Group type: EXPERIMENTAL
Intervention: Attendance at a psychological support group
Number of subjects: 72

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Psychological support group
Number of subjects: 72
Study: 20019345

Group type: EXPERIMENTAL
Intervention: Shared decision making (SDM)
Number of subjects: 612
Study: 17911444

Group type: EXPERIMENTAL
Intervention: Bromocriptine (BRC) 2.5 mg/day and prednisone 10 mg/day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Prednisone 10 mg/day
Number of subjects: 20
Study: 17029177

Group type: EXPERIMENTAL
Intervention: Early mobilization after aortic valve surgery
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Physiological evidence from controlled studies in patients undergoing AVR
Number of subjects: 1200
Study: 12859700

Group type: EXPERIMENTAL
Intervention: bupropion SR 300 mg daily for 7 weeks
Number of subjects: 707

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 707
Study: 10510878

Group type: EXPERIMENTAL
Intervention: Trimebutine maleate (oral treatment for three weeks)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (normal volunteers)
Number of subjects: 63
Study: 8646710

Group type: EXPERIMENTAL
Intervention: 2 mg oral granisetron as a divided dose (1 hour prior to chemotherapy and 12 hours after the start of chemotherapy)
Number of subjects: 697

Group type: COMPARATOR
Intervention: 2 mg oral granisetron as a single dose (1 hour prior to chemotherapy)
Number of subjects: 697
Study: 2049964

Group type: EXPERIMENTAL
Intervention: Ofloxacin 300 mg b.i.d.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Trimethoprim + Sulfamethoxazole (TMP 800 mg + SMX 160 mg), 1 tablet, b.i.d.
Number of subjects: 60
Study: 6342408

Group type: EXPERIMENTAL
Intervention: Orthokeratology (OK)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Conventional rigid contact lenses (Control)
Number of subjects: 31
Study: 30621298

Group type: EXPERIMENTAL
Intervention: Plant-based multivitamin/mineral and phytonutrient (PMP) supplementation for eight weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28338507

Group type: EXPERIMENTAL
Intervention: NY-ESO-1 protein
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: NY-ESO-1 protein + OK-432
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: NY-ESO-1 protein + poly-ICLC
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: NY-ESO-1 protein + OK-432 + poly-ICLC
Number of subjects: 15
Study: 27449548

Group type: EXPERIMENTAL
Intervention: Medication Recommendation Tracking Form (MRTF)
Number of subjects: 482
Study: 24496960

Group type: EXPERIMENTAL
Intervention: Morphine dosing algorithm (5 μg/kg(1.5)/h for neonates with PNA <10 days)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Traditional dosing (for older patients with PNA ≥10 days)
Number of subjects: 38
Study: 21713599

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 120
Study: 19464028

Group type: EXPERIMENTAL
Intervention: High-dose continuous levalbuterol (LEV) 10 mg/hour
Number of subjects: 81

Group type: COMPARATOR
Intervention: Racemic albuterol (RAC) 20 mg/hour
Number of subjects: 81
Study: 17446290

Group type: EXPERIMENTAL
Intervention: Intensive handwashing intervention (handwashing after defecation, after cleaning infants, before preparing food, before eating, and before and after sex)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control group (no intensive handwashing intervention)
Number of subjects: 148
Study: 15745448

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) game coupled with pharmacological analgesia
Number of subjects: 7

Group type: COMPARATOR
Intervention: Pharmacological analgesia only
Number of subjects: 7
Study: 12105816

Group type: EXPERIMENTAL
Intervention: Zinc sulfate supplementation (7.7 micromol zinc sulfate, 50 mg elemental zinc) for 90 days
Number of subjects: 28

Group type: COMPARATOR
Intervention: Cornstarch placebo capsule for 90 days
Number of subjects: 28
Study: 10188745

Group type: EXPERIMENTAL
Intervention: Exercise during the follicular phase (30 min at 75‐80% VO2max)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Exercise during the luteal phase (30 min at 75‐80% VO2max)
Number of subjects: 11
Study: 7582389

Group type: EXPERIMENTAL
Intervention: Xylitol (10% solution, infused intravenously over 2 hours)
Number of subjects: 5
Study: 1710487

Group type: EXPERIMENTAL
Intervention: ProMACE-CytaBOM
Number of subjects: 193

Group type: COMPARATOR
Intervention: ProMACE-MOPP
Number of subjects: 193
Study: 6798826

Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin
Number of subjects: 60
Study: 31418073

Group type: EXPERIMENTAL
Intervention: Relaxation techniques implemented once a day for 30 minutes during 60 consecutive days in addition to routine care
Number of subjects: 80

Group type: COMPARATOR
Intervention: Routine care only
Number of subjects: 80
Study: 30650446

Group type: EXPERIMENTAL
Intervention: Apixaban (10 mg twice daily for 7 days, then 5 mg twice daily thereafter)
Number of subjects: 5365

Group type: COMPARATOR
Intervention: Enoxaparin/warfarin (1 mg/kg twice daily for ≥ 5 days, followed by warfarin)
Number of subjects: 5365

Group type: EXPERIMENTAL
Intervention: Apixaban (with anti-platelet therapy)
Number of subjects: 5365

Group type: COMPARATOR
Intervention: Enoxaparin/warfarin (with anti-platelet therapy)
Number of subjects: 5365
Study: 28249792

Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA) for 40 days after surgical decompression
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo after surgical decompression
Number of subjects: 64
Study: 27212154

Group type: EXPERIMENTAL
Intervention: Injectable bioactive glass
Number of subjects: 58

Group type: COMPARATOR
Intervention: Hydroxyapatite bioceramics
Number of subjects: 58
Study: 23499806

Group type: EXPERIMENTAL
Intervention: GLP-1 infusion at a rate of 1 pmol/kg/min for 4h
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 6
Study: 21163569

Group type: EXPERIMENTAL
Intervention: Intravesical BCG (81 mg)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Intravesical BCG (27 mg)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: BCG (27 mg) with interferon alpha (IFN-α)
Number of subjects: 99
Study: 18297268

Group type: EXPERIMENTAL
Intervention: eMPC group (n = 25) using the laptop‐based algorithm
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (n = 25) treated by an implemented insulin algorithm
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: eMPC group
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 16595318

Group type: EXPERIMENTAL
Intervention: Category-based ethnicity screening question
Number of subjects: 4559

Group type: EXPERIMENTAL
Intervention: Binary plus open-ended ethnicity screening question
Number of subjects: 4559
Study: 12702522

Group type: EXPERIMENTAL
Intervention: Vinorelbine 20 mg/m(2) on days 1 and 8 (group 1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Vinorelbine 30 mg/m(2) on day 1 and 10 mg/m(2) on day 8 (group 2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Vinorelbine 40 mg/m(2) on day 1 (group 3)
Number of subjects: 60
Study: 10898445

Group type: EXPERIMENTAL
Intervention: ACE inhibitor
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control
Number of subjects: 24
Study: 8935815

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control
Number of subjects: 200
Study: 1576853

Group type: EXPERIMENTAL
Intervention: 4-week in-hospital physical training program
Number of subjects: 22

Group type: COMPARATOR
Intervention: No training (untrained group)
Number of subjects: 22
Study: 3921518

Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO) load (920 cal)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Liquid placebo
Number of subjects: 18
Study: 31305131

Group type: EXPERIMENTAL
Intervention: Ribociclib plus letrozole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ribociclib plus fulvestrant
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ribociclib plus tamoxifen/nonsteroidal aromatase inhibitor with ovarian function suppression
Number of subjects: 0
Study: 29477448

Group type: EXPERIMENTAL
Intervention: Indacaterol (110 μg) plus glycopyrronium (50 μg) once per day for 14 days
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 27383664

Group type: EXPERIMENTAL
Intervention: Pharmacogenetic-guided dosing
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: Clinically guided dosing
Number of subjects: 1010

Group type: COMPARATOR
Intervention: EU-PACT strategy
Number of subjects: 1010

Group type: COMPARATOR
Intervention: Fixed-dose group
Number of subjects: 1010
Study: 24096105

Group type: EXPERIMENTAL
Intervention: Continuous T‐CPR
Number of subjects: 95

Group type: COMPARATOR
Intervention: Standard T‐CPR
Number of subjects: 95
Study: 22534813

Group type: EXPERIMENTAL
Intervention: Percutaneous lysis of epidural adhesions
Number of subjects: 92

Group type: COMPARATOR
Intervention: Injection dexamethasone only (Control)
Number of subjects: 92
Study: 19962699

Group type: EXPERIMENTAL
Intervention: Usual postpartum care plus telephone‐based peer support
Number of subjects: 701

Group type: COMPARATOR
Intervention: Usual postpartum care
Number of subjects: 701
Study: 18525027

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 or 80 mg/day
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Atorvastatin (combined with interferon beta‐1a)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 26
Study: 17097736

Group type: EXPERIMENTAL
Intervention: Mean follow-up IOP
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: IOP fluctuation
Number of subjects: 255

Group type: COMPARATOR
Intervention: Glaucoma progression
Number of subjects: 255
Study: 15457423

Group type: EXPERIMENTAL
Intervention: Fondaparinux 2.5 mg for 7 days followed by 21 additional days of fondaparinux
Number of subjects: 656

Group type: COMPARATOR
Intervention: Placebo (short-term prophylaxis)
Number of subjects: 656
Study: 11421879

Group type: EXPERIMENTAL
Intervention: Clarithromycin 250 mg b.d. (PAC 250)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg b.d. (PAC 500)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 154
Study: 10423636

Group type: EXPERIMENTAL
Intervention: Intravenous prostaglandin E1 (PGE1) infusion for 24 hours at a mean dosage of 16 +/- 3 ng/kg/min (range, 10-20 ng/kg/min)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intravenous prostaglandin E1 (PGE1) infusion
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional treatment (Group I)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intravenous prostaglandin E1 (PGE1) during PTCA
Number of subjects: 30
Study: 8275922

Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 65

Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Assessment using MADRS, HARD diagram, checklist for somatic symptoms and side-effects
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Assessment using Hamilton Anxiety Rating Scale (HARS) and sleep questionnaire
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Clinical Global Impression (CGI), Therapeutic Index (TI), Tolerance Global Impression
Number of subjects: 65
Study: 2882768

Group type: EXPERIMENTAL
Intervention: Edrophonium 0.5 mg kg‐1
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Neostigmine 0.05 mg kg‐1
Number of subjects: 20
Study: 30019244

Group type: EXPERIMENTAL
Intervention: T2 group (weaned at 7 days, fed formulated semi‐solid broiler goat concentrate diet)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: T2 group
Number of subjects: 14
Study: 29675114

Group type: EXPERIMENTAL
Intervention: Robotic-Assisted Gait Training (RAGT)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Therapist-Assisted Gait Training (TAGT)
Number of subjects: 19
Study: 27438317

Group type: EXPERIMENTAL
Intervention: Salsalate (3.5 g/d)
Number of subjects: 257

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 257
Study: 24283388

Group type: EXPERIMENTAL
Intervention: Nutritional supplement containing lycopene, β-carotene, and Lactobacillus johnsonii
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nutritional supplement
Number of subjects: 60
Study: 21899713

Group type: EXPERIMENTAL
Intervention: Ursodesoxycholic acid (UDCA) 10 mg/kg orally per day for 24 months
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo tablet for 24 months
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Ursodesoxycholic acid (UDCA)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 19023223

Group type: EXPERIMENTAL
Intervention: Contact anaesthesia
Number of subjects: 120

Group type: COMPARATOR
Intervention: Peribulbar anaesthesia
Number of subjects: 120
Study: 17228035

Group type: EXPERIMENTAL
Intervention: Tanita TBF‐305 body fat analyzer (%FM(T‐Man))
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Tanita TBF‐305 body fat analyzer (%FM(T‐Jebb))
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Four-compartment model (%FM(4C))
Number of subjects: 38
Study: 15746106

Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg daily)
Number of subjects: 5408

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5408

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 5408
Study: 12197590

Group type: EXPERIMENTAL
Intervention: Self-instructional intervention based on the Transtheoretical Model (TM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-instructional intervention based on the TM
Number of subjects: 0
Study: 9808231

Group type: EXPERIMENTAL
Intervention: Conventional dairy products (34 g lactose/d)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Lactose-hydrolyzed dairy products (2 g lactose/d)
Number of subjects: 62
Study: 8074079

Group type: EXPERIMENTAL
Intervention: Micronutrient supplements
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 2687426

Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Having more siblings
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Maternal smoking and low social class
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: House dust antigen
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Season of birth (Autumn)
Number of subjects: 483
Study: 31875256

Group type: EXPERIMENTAL
Intervention: Elimination of potentially irritating beverages (PIBs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diet/exercise recommendations (Control)
Number of subjects: 0
Study: 31507001

Group type: EXPERIMENTAL
Intervention: iHEART intervention with AliveCor KardiaMobile ECG monitor
Number of subjects: 238

Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Recurrence during the first month after ablation
Number of subjects: 238
Study: 28643661

Group type: EXPERIMENTAL
Intervention: General or spinal anaesthesia
Number of subjects: 100

Group type: COMPARATOR
Intervention: Local anaesthesia
Number of subjects: 100
Study: 25423308

Group type: EXPERIMENTAL
Intervention: Manual-thrust manipulation (MTM)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Mechanical-assisted manipulation (MAM)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Usual medical care (UMC)
Number of subjects: 107
Study: 24012035

Group type: EXPERIMENTAL
Intervention: Severe calcification
Number of subjects: 755